Wall Street Zen Upgrades Cogent Biosciences (NASDAQ:COGT) to “Hold”

Cogent Biosciences (NASDAQ:COGT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts have also recently commented on COGT. Piper Sandler boosted their target price on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. Guggenheim boosted their price objective on shares of Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Wedbush restated an “outperform” rating and set a $55.00 target price on shares of Cogent Biosciences in a research note on Friday, May 29th. HC Wainwright boosted their price target on Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.40.

Cogent Biosciences Stock Performance

NASDAQ:COGT opened at $36.73 on Friday. Cogent Biosciences has a 12 month low of $11.60 and a 12 month high of $43.73. The business’s 50-day moving average is $38.49 and its two-hundred day moving average is $36.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 13.57 and a quick ratio of 13.57. The firm has a market capitalization of $6.37 billion, a PE ratio of -17.00 and a beta of 0.38.

Cogent Biosciences (NASDAQ:COGT) last announced its earnings results on Monday, August 10th. The technology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. Research analysts predict that Cogent Biosciences will post -2.24 earnings per share for the current fiscal year.

Institutional Trading of Cogent Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of COGT. EverSource Wealth Advisors LLC lifted its holdings in Cogent Biosciences by 1,164.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after buying an additional 652 shares during the last quarter. J.Safra Asset Management Corp bought a new stake in shares of Cogent Biosciences in the 2nd quarter valued at approximately $27,000. Osaic Holdings Inc. increased its holdings in shares of Cogent Biosciences by 41.4% in the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock valued at $33,000 after acquiring an additional 1,333 shares during the last quarter. Strs Ohio acquired a new stake in shares of Cogent Biosciences during the 1st quarter valued at approximately $36,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of Cogent Biosciences during the 4th quarter valued at approximately $37,000.

More Cogent Biosciences News

Here are the key news stories impacting Cogent Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $55 price objective for COGT, signaling confidence in Cogent Biosciences’ longer-term growth prospects. HC Wainwright analyst coverage
• Positive Sentiment: The analyst expects losses to narrow significantly in 2027, forecasting quarterly EPS of $(0.50), $(0.38), $(0.26), and $(0.15), resulting in a full-year loss of $(1.28). The improving trajectory may support the stock’s valuation if Cogent’s pipeline advances as expected. Cogent Biosciences 2027 earnings estimates
• Neutral Sentiment: HC Wainwright initiated its 2027 estimates, including a $(1.28) full-year EPS forecast. These projections provide new expectations for investors but do not represent a change to the company’s operating results. Cogent Biosciences analyst estimates
• Negative Sentiment: HC Wainwright reduced its 2026 EPS forecasts, lowering Q3 estimates to $(0.59) from $(0.56), Q4 estimates to $(0.62) from $(0.57), and full-year estimates to $(2.37) from $(2.21). The revisions indicate higher expected losses in the near term and could limit upside despite the bullish rating. Cogent Biosciences 2026 earnings estimate revisions

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.